百花医药筹划控制权变更，米恩华家族或退出？

Core Viewpoint - The controlling family of Baihua Pharmaceutical (600721.SH), led by Mienhua Mi, is planning a potential transfer of shares that may lead to a change in the company's control [1] Group 1: Company Background - Baihua Pharmaceutical, originally known as "Baihua Village," was the first listed company of the Xinjiang Production and Construction Corps, with its stock listed on the Shanghai Stock Exchange in 1996 [2] - The company has undergone multiple asset restructurings, transitioning from retail and trade to pharmaceutical research and development services after acquiring Nanjing Huawai Pharmaceutical in 2016 [2] Group 2: Financial Performance - Baihua Pharmaceutical has experienced significant fluctuations in net profit from 2019 to 2024, with figures of 34.38 million, -320 million, 59.83 million, -34.76 million, 12.97 million, and 41.48 million yuan respectively [3] - In the first nine months of 2025, the company reported a revenue of 299 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, up 36.41% compared to the previous year [3] Group 3: Shareholding Changes - In December 2024, the controlling shareholder of Baihua Pharmaceutical changed, with the actual controllers now including Mienhua Mi, his son Mizanqi Mi, and Yang Xiaoling, holding a combined 20.71% of the total shares [1][2] - Following the change in control, the shareholding structure of Hualing Industrial Group also shifted, with Xinjiang Commerce and Logistics Asset Management Co., Ltd. becoming the controlling shareholder [4] Group 4: Future Outlook - Baihua Pharmaceutical has been suspended from trading since December 29, with expectations that the company's future direction will be clarified within 2025 [5]